CareDx, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Thursday, March 24, 2016 4:01:12 PM ET
CareDx, Inc. (CDNA ), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today reported financial results for the fourth quarter and full year ended December 31, 2015.
-- For the full year 2015, revenue was $28.1 million versus $27.3 million in 2014, an increase of 3%. Total revenue in 2014 included a $1.1 million one-time payment from LabCorp recorded in the fourth quarter. <ul type="circle"><p>-- Revenue from AlloMap(R), the Companys flagship molecular diagnostic surveillance solution, grew to $27.9 million in 2015 compared to $25.8 million in 2014, an increase of 8%.
-- Revenue from AlloMap(R), the Companys flagship molecular diagnostic surveillance solution, grew to $27.9 million in 2015 compared to $25.8 million in 2014, an increase of 8%.
-- Total revenue for the fourth quarter was $6.6 million, which included a change in revenue recognition from accrual to cash accounting for royalties we receive on a technology license. <ul type="circle"><p>-- Fourth quarter AlloMap revenue was $6.7 million, up 1% year over year.
-- Fourth quarter AlloMap revenue was $6.7 million, up 1% year over year.
-- AlloMap revenue in the fourth quarter was negatively impacted by reduced collections from an external vendor as we transitioned to our in-house team.
-- Over 13,000 AlloMap patient results were provided in the year ended December 31st, 2015, up 10% over 2014.
-- CareDx and Diaxonhit announced completion of technology transfer of AlloMap in Europe
-- A positive coverage decision for AlloMap was received from TRICARE(R) covering over 9 million lives of U.S. military members and their families
-- Completed analytical validation of AlloSure(TM), the companys transplant surveillance solution under development based on cfDNA technology.
-- Announced an agreement to acquire 78% percent of the outstanding shares of Allenex AB, a Swedish organ transplant company.
"I am pleased with the continued growth in AlloMap and our progress with the development of AlloSure, demonstrating the utility of cell-free DNA technology as a biomarker in organ transplantation," said President and Chief Executive Officer, Peter Maag. "And I am very excited about the combination with Allenex, which will create an international transplantation diagnostics company with expanded distribution and growth potential. Together we will offer patients and clinicians a broader range of transplant diagnostic solutions, which should enhance our ability to improve patient outcomes."
Fourth Quarter Financial Results
Revenue for the three months ended December 31, 2015 was $6.6 million, versus $8.0 million in the same period in 2014. The 2014 period benefited from a $1.1 million one-time payment from LabCorp.
For the fourth quarter of 2015, net loss was $4.8 million compared to net loss of $5,000 in the fourth quarter of 2014.
Basic and diluted net loss per share each were $0.40 in the fourth quarter of 2015, compared to basic and diluted earnings per share of $0.00, respectively, in the fourth quarter of 2014.
Cash and cash equivalents were $29.9 million as of December 31, 2015.
Full Year Financial Results
Revenue for the fiscal year ended December 31, 2015 was $28.1 million, up from $27.3 million for fiscal year 2014.
For the full year 2015, net loss was $13.7 million compared to net income of $0.8 million for 2014. Basic and diluted loss per share were $1.16 for fiscal year 2015 compared to basic and diluted income per share of $0.13 and $0.10 for fiscal year 2014.
Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or +1(678) 304-6848 for international callers. Please reference Conference ID: 37676864. To listen to a live webcast, please visit the investor relations section of CareDxs website at: www.CareDx.com.
A replay of the call will be available beginning March 24, 2016 at 4:30pm PT/7:30pm ET through midnight on March 25, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 37676864. The webcast will also be available on CareDxs website for one year following the completion of the call.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap(R), a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also developing additional products for transplant monitoring using a variety of technologies, including AlloSure(TM), its next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com.
Forward Looking Statements
In addition to the historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the risk that our revenue may not be as high as anticipated, risks related to the successful consummation and integration of the acquisition of Allenex AB, risks relating to our dependence on the sales of one test, AlloMap, for substantially all of our current revenue, our dependence on Medicare for a substantial portion of our revenue, our dependence on health insurers and other third-party payers to provide coverage for our current test and future tests, if any, risks of increased competition from other market participants, many of whom have substantially greater resources than us and risks related to our development and commercialization of additional diagnostic solutions. These factors, together with those that are described in greater detail in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed by us with the SEC on March 31, 2015, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the most recent reporting period are not necessarily indicative of our operating results for any future periods.
Statements of Operations
(in thousands, except share and per share data)
Three-Month Ended December 31, Year Ended December 31,
2015 2014 2015 2014
Testing revenue $ 6,734 $ 6,697 $ 27,881 $ 25,842
Collaboration and license revenue (86 ) 1,255 263 1,464
Total revenue 6,648 7,952 28,144 27,306
Cost of testing 2,486 2,204 10,273 8,541
Research and development 2,704 1,298 9,333 3,846
Sales and marketing 1,896 1,635 8,349 6,472
General and administrative 3,694 2,349 12,247 8,436
Change in estimated fair value of contingent consideration 330 37 (126 ) (1,239 )
Total operating expenses 11,110 7,523 40,076 26,056
Loss from operations (4,462 ) 429 (11,932 ) 1,250
Interest expense, net (253 ) (389 ) (1,587 ) (2,116 )
Other expense, net (47 ) (45 ) (188 ) 147
Loss before income taxes (4,762 ) (5 ) (13,707 ) (719 )
Income tax benefit - - - 1,500
Net (loss) income $ (4,762 ) $ (5 ) $ (13,707 ) $ 781
Net (loss) income per share:
Basic $ (0.40 ) $ - $ (1.16 ) $ 0.13
Diluted $ (0.40 ) $ - $ (1.16 ) $ 0.10
Shares used to compute net (loss) income per share:
Basic 11,902,325 11,802,241 11,860,885 5,815,928
Diluted 11,902,325 12,129,058 11,860,885 9,283,001
As of December 31,
Cash & cash equivalents $ 29,888 $ 36,431
Accounts receivable 2,367 2,687
Inventory 766 686
Prepaid and other assets 1,341 542
Total current assets 34,362 40,346
Property and equipment, net 2,425 1,968
Intangible assets, net 6,650 6,650
Goodwill 12,005 12,005
Restricted cash 147 147
Other noncurrent assets 49 25
Total assets $ 55,638 $ 61,141
LIABILITIES & EQUITY
Accounts payable $ 1,644 $ 1,128
Accrued payroll 2,366 1,684
Accrued and other liabilities 2,892 1,616
Accrued royalties 242 241
Deferred revenue 142 505
Current portion of long-term debt 2,866 5,961
Total current liabilities 10,152 11,135
Deferred rent, net of current portion 1,426 1,684
Deferred revenue, net of current portion 703 471
Long term debt, net of current portion 12,887 5,451
Contingent consideration 948 1,074
Other liabilities 28 28
Total liabilities 26,144 19,843
Common stock 12 12
Additional paid in capital 202,564 200,661
Accumulated deficit (173,082 ) (159,375 )
Total stockholders equity 29,494 41,298
Total liabilities and equity $ 55,638 $ 61,141
Investor Relations Contact:
<img src="http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzYyNDM4Nzg=" alt="" width="1" height="1"/>